Pfizer Inc. (PFE)
Pfizer's Obesity and Oncology Pipeline Sets Up a Catalyst-Rich 2026
PFE targets a catalyst-rich 2026 with pivotal obesity and oncology studies, key data readouts, and regulatory decisions across its pipeline.
Why Pfizer's Current Price May Be Too Cheap to Ignore
Pfizer (NYSE:PFE | PFE Price Prediction) is one of those names where the headline narrative (COVID hangover, patent cliff) keeps overshadowing what is actually a defensive cash machine trading at a single-digit forward multiple.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Mailbag: A Follow-Up on Pfizer & Other Questions
Two weeks ago, I said that one of my favorite stocks right now is Pfizer (PFE). The pharmaceutical giant is in the middle of a transformational period with the goal to return to growth by 2029.
Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion
The partnership includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates. Innovent will will co-commercialize with Pfizer in the U.S. and Europe and share profits but retain rights in the Greater China market.
Insiders Aren't Buying Pfizer Stock at $26 and That's Actually a Good Thing
The smart money on Pfizer (NYSE: PFE | PFE Price Prediction) is sending a quieter signal than the financial press typically rewards: institutional analysts are constructive, insiders are not transacting in size in either direction, and the dividend yield is doing the heavy lifting.
Pfizer Bets on New & Acquired Drugs to Offset Its LOE Pressure?
PFE is banking on new launches, Seagen assets and pipeline progress to counter a looming patent cliff through 2030.
J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?
JNJ's diversified pharma and MedTech growth, pipeline progress and stronger 2026 outlook give it an edge over PFE.
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer: Reduced TrumpRx/Patent Risks Meet Accretive M&A Efforts - Reiterate Buy
PFE's aggressive M&A and in-house R&D efforts are paying off, with the growth portfolio (newly launched/acquired products) already delivering $3.1B in revenues in FQ1'26 (+22% YoY operationally). LOE risks are mitigated by delayed Vyndamax generic entry to mid-2031, supporting the management's high single-digit 5Y revenue growth guidance from 2029 onwards. PFE's intermediate-term performance is expected to remain lumpy, but the cost saving efforts, strong interest coverage, and dividend sustainability underpin its compelling investment thesis.
FQ1 Healthcare Dividend Roundup: Johnson & Johnson Keeps Outshining Pfizer
Johnson & Johnson offers a superior return/risk profile versus Pfizer, driven by consistency and operational stability. PFE's far lower valuation (FWD P/E 8.55x, PEGY 0.97x) and far higher yield (6.79%) are certainly attractive. But JNJ's 63-year streak of dividend growth, lower payout ratio (48.46%), ongoing buybacks, and stable inventory all point to far superior consistency.
Pfizer Builds Oncology Growth Around Padcev and Pipeline Expansion
PFE bets on Padcev, biosimilars and late-stage pipeline candidates to drive long-term oncology growth amid pressure on legacy drugs.
